Press-release for stocks related to fda for orange

Prices are updated after-hours

tags : Fda entities : Orange

save search

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Published: 2024-04-03 (Crawled : 12:00) - globenewswire.com
IKT | News | $2.13 0.19% 28K

Health Technology

| -2.33% | O: -0.93% H: 7.04% C: 0.94%
fda meeting hypertension therapeutics

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -7.19% | O: -2.69% H: 0.0% C: 0.0%
VRCA | $6.91 -2.13% -2.17% 200K

Health Technology

| 39.53% | O: -5.53% H: 14.44% C: 11.3%
fda pharmaceuticals

FDA Roundup: February 23, 2024
Published: 2024-02-23 (Crawled : 23:00) - fda.gov
FNCTF | News | $11.0354 -20.84% 34K

Communications

| Email alert Add to watchlist
fda

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -6.87% | O: 0.68% H: 0.0% C: 0.0%
ALPMF | $9.594 43.47% 2.2K

Health Technology

| -22.28% | O: -2.79% H: 0.62% C: 0.62%
ALPMY | $9.46 -1.11% 500K

Manufacturing

| -23.82% | O: -2.2% H: 0.0% C: -0.27%
cresemba fda children

West Receives FDA 510(k) Clearance for Vial2Bag Advanced® 13mm Admixture Device
Published: 2023-12-04 (Crawled : 20:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -7.88% | O: -1.09% H: 0.0% C: 0.0%
WST | $377.33 -0.01% 0.0% 320K

Health Technology

| 7.55% | O: -0.7% H: 0.17% C: -1.42%
advanced fda device west clearance

Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan
Published: 2023-11-30 (Crawled : 08:00) - globenewswire.com
SCLX | $0.8942 -23.57% -30.84% 2.8M

| -16.43% | O: -2.14% H: 2.19% C: -8.76%
ztlido fda company japan

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
Published: 2023-11-27 (Crawled : 23:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -13.31% | O: -2.99% H: 0.0% C: 0.0%
SWTX | News | $42.48 -3.7% -3.84% 810K

Health Technology

| 110.74% | O: 10.74% H: 16.83% C: 7.17%
fda approval tumors treatment therapeutics

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
Published: 2023-11-27 (Crawled : 13:30) - globenewswire.com
EVOK | $0.489 -10.93% -12.27% 21K

Health Technology

| -62.4% | O: 0.0% H: 10.52% C: 4.0%
fda pharma patent gimoti

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
Published: 2023-11-27 (Crawled : 12:00) - prnewswire.com
RDHL | $0.4301 11.57% 10.37% 660K

Health Technology

| 23.61% | O: 122.69% H: 62.25% C: 42.33%
talicia fda biopharma grant market

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
BTAI | $2.56 -1.16% -1.17% 240K

Health Technology

| -53.72% | O: -35.39% H: 19.38% C: 18.54%
fda update trial therapeutics financial results

Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -5.19% | O: -2.28% H: 0.0% C: 0.0%
phexxi fda approval market

RedHill Announces FDA sNDA Approval for Talicia®
Published: 2023-09-18 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -2.17% | O: 2.39% H: 0.0% C: 0.0%
RDHL | $0.4301 11.57% 10.37% 660K

Health Technology

| -54.12% | O: 14.12% H: 5.15% C: -16.39%
talicia fda approval

Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
Published: 2023-08-29 (Crawled : 15:30) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -2.77% | O: 1.76% H: 0.0% C: 0.0%
camcevi fda patent pharmaceuticals

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Published: 2023-08-29 (Crawled : 11:00) - globenewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -2.77% | O: 1.76% H: 0.0% C: 0.0%
EGRX | $4.505 2.62% 2.55% 140K

Health Technology

| -71.44% | O: 0.49% H: 3.15% C: 2.79%
ea-114 fda breast positive cancer treatment pharmaceuticals women meeting

FDA Roundup: August 15, 2023
Published: 2023-08-15 (Crawled : 20:00) - fda.gov
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -1.82% | O: 1.51% H: 0.0% C: -1.03%
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -28.17% | O: -0.71% H: 1.45% C: 0.97%
fda

Reglagene gets crucial TCA Orange County funding for FDA brain cancer therapy studies
Published: 2023-08-01 (Crawled : 19:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K

Communications

| Email alert Add to watchlist
fda cancer funding therapy

Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA Submission
Published: 2023-07-14 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K

Communications

| -2.77% | O: 0.97% H: 0.0% C: 0.0%
NTRB | $4.18 -2.11% -3.39% 24K

Manufacturing

| 77.92% | O: 25.0% H: 33.0% C: 7.67%
fda platform submission

BrainStorm Touts Biomarker Data for ALS Candidate After Two FDA Rebuffs
Published: 2023-07-10 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K

Communications